Free Trial
NASDAQ:NRXS

NeurAxis Q1 2024 Earnings Results & Report

NeurAxis logo
$7.74 +1.21 (+18.53%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$7.78 +0.04 (+0.52%)
As of 10/15/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NeurAxis reported Q1 2024 earnings on May 20, 2024. The company reported EPS of -$0.32, while revenue was $0.65 million.

Earnings Announcement Details

Quarter
Q1 2024
Report Date

NeurAxis EPS Results

Actual EPS
-$0.32
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NeurAxis Revenue Results

Actual Revenue
$0.65 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

NeurAxis' next earnings date is estimated for Monday, November 9, 2026, based on past reporting schedules.

Conference Call Resources

NeurAxis Q1 2024 Earnings FAQ

NeurAxis (NASDAQ:NRXS) reported earnings of -$0.32 per share for Q1 2024. The report was announced on Monday, May 20, 2024.

NeurAxis reported revenue of $0.65 million for Q1 2024.

NeurAxis' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for NeurAxis on the company's earnings history page.

NeurAxis Earnings Headlines

Aetna deems IB-Stim by NeurAxis medically necessary
I'm giving you a space stock today. Free.
On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on.tc pixel
NeurAxis Declares Q3 Stock Dividend on Preferred Shares
See More NeurAxis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NeurAxis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeurAxis and other key companies, straight to your email.

About NeurAxis

NeurAxis (NASDAQ:NRXS) is a medical technology company focused on developing and commercializing neuromodulation therapies for functional gastrointestinal disorders. The company’s primary product is IB-Stim, a minimally invasive device that delivers percutaneous electrical nerve field stimulation through the external ear.

IB-Stim is designed to modulate neural pathways associated with functional abdominal pain and related gastrointestinal symptoms. It has been cleared by the U.S. Food and Drug Administration for use in patients, including adolescents, with functional abdominal pain associated with irritable bowel syndrome. The therapy is administered by qualified healthcare professionals and is intended to complement broader clinical care.

NeurAxis is headquartered in Carmel, Indiana, and primarily serves the U.S. healthcare market through physicians and other medical providers. The company’s activities center on expanding awareness and adoption of its neuromodulation platform in gastroenterology, pain management and related specialties.

View NeurAxis Profile